Skip to main content
. 2018 Jun 25;8:9657. doi: 10.1038/s41598-018-27987-w

Table 5.

Uni- and multivariate association of response with CDR1-AS, hsa-miR-7 and other clinical variables in the predictive cohort.

Parameters base model univariate model multivariate model
n OR (95% CI) P OR (95% CI) P
188
Age at start 1 st -line tamoxifen
≤55 years 75 1 1
56–70 years 67 1.63 (0.82–3.25) 0.16 1.23 (0.55–2.72) 0.61
>70 years 46 3.06 (1.29–7.23) 0.011 2.05 (0.81–5.18) 0.13
Disease-free interval
≤1 year 76 1 1
1–3 years 48 1.52 (0.71–3.25) 0.28 1.44 (0.63–3.30) 0.38
>3 years 64 2.07 (0.99–4.28) 0.05 1.88 (0.86–4.14) 0.12
Dominant site of relapse
Local regional 21 1 1
Bone 101 0.25 (0.07–0.92) 0.037 0.20 (0.05–0.77) 0.020
Other distant metastasis 66 0.41 (0.11–1.56) 0.19 0.28 (0.07–1.19) 0.08
Hormone/Growth factor receptors*
ER (log continuous ESR1) 188 1.65 (1.22–2.23) 0.001 1.65 (1.15–2.36) 0.006
PR (log continuous PGR) 188 1.07 (0.92–1.25) 0.39 1.00 (0.84–1.20) 0.99
HER2 (ERBB2) status
  Not amplified 165 1 1
  Amplified 23 0.60 (0.25–1.45) 0.26 0.97 (0.33–2.85) 0.96
hsa-miR-7 separately added to the base model
CDR1-AS (log continuous) 188 1.01 (0.78–1.31) 0.96
hsa-miR-7 (log continuous) 188 0.76 (0.60–0.96) 0.023 0.73 (0.57–0.95) 0.017
≤median 94 1 1
>median 94 0.56 (0.30–1.03) 0.064 0.59 (0.30–1.16) 0.13

The association of the different parameters, including CDR1-AS and hsa-miR-7 expression, with the therapy response in the predictive cohort is displayed on the left side of the table. The hormone/growth factor receptor expression values used in this table were determined by qPCR. * Cut-offs for positive and negative hormone receptor/growth factor status were established as previously described56,57. The same parameters are assessed with a multivariate model on the right side. n = number of patients, OR = odds ratio, CI = confidence interval, and P = p-value. Significant p-values are highlighted in bold.